先进的口服小分子对炎症性肠病的有效性和安全性:系统性审查和元分析
Virginia Solitano1,2,3, Sudheer K Vuyyuru1,2, John K MacDonald2
1Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.
新的口服小分子药物,包括JAK抑制剂和S1P受体调节剂,在性结肠炎和克罗恩病等炎症性肠道疾病中有效诱导缓解,其安全性与安慰剂相似.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 口服小分子药物 (SMD) 正在成为炎症性肠病 (IBD) 的关键疗法.
- 本综述重点关注Janus激酶 (JAK) 抑制剂和性结肠炎 (UC) 和克罗恩病 (CD) 的sphingosine-1-phosphate (S1P) 受体调节剂.
结论:
- 雅克抑制剂和S1P受体调节剂是诱导IBD缓解的有效治疗选择.
- 这些口服SMD为UC和CD提供了有价值的治疗策略,在严重感染方面,其安全性与安慰剂相当.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Constipation-Predominant IBS
